JAK Inhibitor Safety Concerns vs Rebates: Which Will Impact Atopic Dermatitis Drug Access More?
Executive Summary
ICER discussion on the health benefit of several upcoming drugs for atopic dermatitis, including several JAK inhibitors, touches on safety concerns and the likelihood that increased competition will open the door to higher list prices and rebating in the class.
You may also be interested in...
Keeping Track: US FDA Clears Bylvay, Fexinidazole, Gives Retifanlimab CRL; JAK Inhibitor Class Delays
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
JAK-Inhibitor Review Delays Spur Talk Of US FDA Panel Meeting On Class Safety
After Pfizer saw increased risks in a surveillance study of Xeljanz, three other products have also seen their user fee dates pushed back; if FDA were to convene an expert panel, it could lead to more consistent labeling across the class, as requested in a recent citizen petition.
Sanofi, Regeneron Setting 'New Paradigm' With Dupixent Pricing In US?
Companies employed collaborative outreach with payers to arrive at 'responsible' price for atopic dermatitis biologic.